What's Happening?
Anixa Biosciences, in collaboration with Moffitt Cancer Center, has completed dosing the fourth cohort in its Phase 1 clinical trial for a novel CAR-T therapy targeting recurrent ovarian cancer. The trial, which uses FSHR-targeted CAR-T/CER-T technology, has shown promising results with several patients surpassing median survival expectations. The therapy targets the follicle-stimulating hormone receptor, which is expressed on ovarian cells and certain cancer cells. The fourth cohort received a significantly higher dose compared to the first cohort, with no dose-limiting toxicities observed. The trial aims to assess safety and identify the maximum tolerated dose, with the fifth cohort set to begin after a 30-day safety review.
Why It's Important?
The trial's promising results could mark a significant advancement in ovarian cancer treatment, offering hope for patients with recurrent disease who have limited options. The absence of severe side effects at higher doses suggests the therapy's potential for broader application. This development could influence future cancer immunotherapy strategies, potentially leading to more effective treatments with fewer side effects. The collaboration between Anixa and Moffitt highlights the importance of partnerships in advancing cancer research and treatment.
What's Next?
Pending the safety review of the fourth cohort, the trial will proceed with the fifth cohort, which will receive an even higher dose. The ongoing assessment of safety and efficacy will determine the therapy's potential for further clinical development. If successful, this could lead to expanded trials and eventual regulatory approval, providing a new treatment option for ovarian cancer patients.
